Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study.

IF 1.6 Q4 ONCOLOGY
International Journal of Surgical Oncology Pub Date : 2019-05-02 eCollection Date: 2019-01-01 DOI:10.1155/2019/2912361
Shokouh Taghipour Zahir, Zahra Heidarymeybodi, Sogol AleSaeidi
{"title":"Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study.","authors":"Shokouh Taghipour Zahir, Zahra Heidarymeybodi, Sogol AleSaeidi","doi":"10.1155/2019/2912361","DOIUrl":null,"url":null,"abstract":"<p><p>This study examines survival time in patients with small bowel tumors and determines its contributing factors. In this retrospective analytical study, the medical records of 106 patients with small bowel cancer (from 2006 to 2011) were investigated. The patients' data were extracted, including age, gender, clinical presentation, location of tumor, histological type, grade of tumor, site of metastasis, and type of treatment. The Kaplan-Meier test was used to estimate the overall survival time and the Log-rank test to compare the survival curves. The Cox regression was also used to evaluate the effect of the confounding variables on survival time. This study was conducted on 106 patients with a median age of 60 years (Min: 7, Max: 87). The tumor types included adenocarcinoma (n=78, 73.6%), MALToma (n=22, 20.8%), neuroendocrine tumors (n=4, 3.8%), and sarcoma (n=2. 1.8%). Grade 3 adenocarcinomas had a significantly lower survival time (HR: 1.48, 95% CI: 0.46-2.86; P=.001). Combined therapy (chemotherapy and surgery) vs. single-therapy (only surgery) had no significant effects on the survival of the patients with MALToma (5 vs. 3 months, 95% CI: 1.89-5.26; P=.06). There were no significant differences between the survival time in adenocarcinoma and MALToma (12 vs. 20 months, 95% CI: 6.24-24.76; P=.49). Tumor grade was the only independent prognostic factor that affected survival in adenocarcinoma. The patients diagnosed with MALToma in the study also had a poor prognosis, and the type of treatment had no significant effect on their survival.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2019-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521306/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/2912361","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study examines survival time in patients with small bowel tumors and determines its contributing factors. In this retrospective analytical study, the medical records of 106 patients with small bowel cancer (from 2006 to 2011) were investigated. The patients' data were extracted, including age, gender, clinical presentation, location of tumor, histological type, grade of tumor, site of metastasis, and type of treatment. The Kaplan-Meier test was used to estimate the overall survival time and the Log-rank test to compare the survival curves. The Cox regression was also used to evaluate the effect of the confounding variables on survival time. This study was conducted on 106 patients with a median age of 60 years (Min: 7, Max: 87). The tumor types included adenocarcinoma (n=78, 73.6%), MALToma (n=22, 20.8%), neuroendocrine tumors (n=4, 3.8%), and sarcoma (n=2. 1.8%). Grade 3 adenocarcinomas had a significantly lower survival time (HR: 1.48, 95% CI: 0.46-2.86; P=.001). Combined therapy (chemotherapy and surgery) vs. single-therapy (only surgery) had no significant effects on the survival of the patients with MALToma (5 vs. 3 months, 95% CI: 1.89-5.26; P=.06). There were no significant differences between the survival time in adenocarcinoma and MALToma (12 vs. 20 months, 95% CI: 6.24-24.76; P=.49). Tumor grade was the only independent prognostic factor that affected survival in adenocarcinoma. The patients diagnosed with MALToma in the study also had a poor prognosis, and the type of treatment had no significant effect on their survival.

Abstract Image

Abstract Image

小肠肿瘤患者的预后因素和生存时间:回顾性观察研究
本研究探讨了小肠肿瘤患者的生存时间,并确定了其诱因。在这项回顾性分析研究中,研究人员调查了 106 名小肠癌患者(2006 年至 2011 年)的病历。研究提取了患者的数据,包括年龄、性别、临床表现、肿瘤位置、组织学类型、肿瘤分级、转移部位和治疗类型。用 Kaplan-Meier 检验估计总生存时间,用 Log-rank 检验比较生存曲线。此外,还使用 Cox 回归评估混杂变量对生存时间的影响。这项研究的对象为 106 名患者,中位年龄为 60 岁(最小:7 岁,最大:87 岁)。肿瘤类型包括腺癌(78 例,占 73.6%)、MALToma(22 例,占 20.8%)、神经内分泌肿瘤(4 例,占 3.8%)和肉瘤(2 例,占 1.8%)。3级腺癌的生存时间明显更短(HR:1.48,95% CI:0.46-2.86;P=.001)。联合疗法(化疗和手术)与单一疗法(仅手术)对MALToma患者的生存期没有显著影响(5个月与3个月,95% CI:1.89-5.26;P=.06)。腺癌和MALToma的生存期没有明显差异(12个月对20个月,95% CI:6.24-24.76;P=.49)。肿瘤分级是影响腺癌生存期的唯一独立预后因素。研究中被诊断为MALToma的患者预后也很差,治疗类型对其生存期没有显著影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
5
审稿时长
20 weeks
期刊介绍: International Journal of Surgical Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of surgical oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信